“Over the weekend at ESMOGI25, our botensilimab/balstilimab investigational combo presented new MSS colorectal cancer data, showing consistent results over extended follow-up. See the full presentation here.”
“Over the weekend at ESMOGI25, our botensilimab/balstilimab investigational combo presented new MSS colorectal cancer data, showing consistent results over extended follow-up. See the full presentation here.”